Aranesp Joins Other EPO Products With Hemoglobin Treatment Goal Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's Procrit and Amgen's Epogen previously added similar labeling language cautioning physicians not to treat patients to hemoglobin levels above 12 grams per deciliter. The warnings are based on ex-U.S. studies of J&J's Eprex and Roche's NeoRecormon.